secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001628280-25-032155
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics shareholders approve doubling authorized common shares to 300M at annual meeting
--------------------------------------------------------------------------------

- Shareholders elected Ronald Cooper, Donna Grogan, and Steven Hoerter as Class II directors for terms expiring 2028.
- Non-binding advisory vote on executive compensation passed with 48.85M for vs 0.89M against.
- Ratification of KPMG as auditor for FY2025 approved with 60.18M for, 0.08M against.
- Amendment to increase authorized common shares from 150M to 300M approved with 39.55M for, 20.66M against.
- Certificate of Amendment filed and effective June 18, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025032155/0001628280-25-032155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025032155/cccc-20250618.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-032155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer